![Scott Jackson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Jackson
Directeur/Membre du Conseil chez
MACROGENICS, INC.
Fortune : 217 010 $ au 31/05/2026
Profil
Scott T.
Jackson is currently an Independent Director at MacroGenics, Inc. since 2017, an Independent Director at Spero Therapeutics, Inc. since 2020, and a Director at Philabundance.
Former roles include Chief Executive Officer & Director at Jazz Pharmaceuticals Therapeutics, Inc. from 2008 to 2016, Chairman at Mural Oncology Plc from 2023 to 2025, Independent Director at GlycoMimetics, Inc. from 2018 to 2025, Principal at Centocor, Inc. from 2002 to 2004, Principal at ImClone LLC, Principal at Eli Lilly & Co. from 1988 to 1993, Principal at Smithkline Beecham Plc, Vice President-Marketing at YM BioSciences, Inc. from 2004 to 2007, Vice President-Marketing at YM BioSciences USA, Inc. from 2004 to 2006, and Trustee-Eastern Pennsylvania Chapter at Blood Cancer United, Inc. from 2013 to 2019.
Education includes an MBA from the University of Notre Dame and undergraduate studies at Philadelphia College of Pharmacy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SPERO THERAPEUTICS, INC. 0,09 % | 01/04/2026 | 55 000 ( 0,09 % ) | 155 650 $ | 31/05/2026 |
MACROGENICS, INC. 0,02 % | 19/05/2026 | 14 750 ( 0,02 % ) | 61 360 $ | 31/05/2026 |
Postes actifs de Scott Jackson
| Sociétés | Poste | Début |
|---|---|---|
| MACROGENICS, INC. | Directeur/Membre du Conseil | 25/01/2017 |
| SPERO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 16/04/2020 |
Philabundance
 Philabundance Services to the Health IndustryHealth Services Provides food services to the community | Directeur/Membre du Conseil | - |
Anciens postes connus de Scott Jackson
| Sociétés | Poste | Fin |
|---|---|---|
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Directeur/Membre du Conseil | 21/02/2025 |
The Leukemia & Lymphoma Society, Inc.
 The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit organization dedicated to funding research, education and support services for all blood cancers | Corporate Officer/Principal | 01/06/2019 |
| CELATOR PHARMACEUTICALS INC | Directeur Général | 12/07/2016 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Sales & Marketing | 01/05/2007 |
Formation de Scott Jackson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
55
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Manufactures healthcare products | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Smithkline Beecham Plc
 Smithkline Beecham Plc Pharmaceuticals: OtherHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Health Technology |
Eximias Pharmaceutical Corp.
 Eximias Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for treatment of cancer disorders | Health Technology |
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat acute myeloid leukemia and AML with myelodysplasia in children & adults | Health Technology |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Philabundance
Philabundance Services to the Health IndustryHealth Services Provides food services to the community | Health Services |
GlycoMimetics, Inc.
GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit organization dedicated to funding research, education and support services for all blood cancers | Commercial Services |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Philadelphia College of Pharmacy
 Philadelphia College of Pharmacy Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
